RBC Capital Maintains Outperform on Iterum Therapeutics, Lowers Price Target to $10

RBC Capital analyst Gregory Renza maintains Iterum Therapeutics (NASDAQ:ITRM) with a Outperform and lowers the price target from $14 to $10.

Benzinga · 12/11/2019 14:02

RBC Capital analyst Gregory Renza maintains Iterum Therapeutics (NASDAQ:ITRM) with a Outperform and lowers the price target from $14 to $10.